

Pharmaceutical Benefits Scheme (PBS) Listings

1 December 2025

Please find below information relating to new and amended Pharmaceutical Benefits Scheme (PBS) listings implemented on **1 December 2025**.

This information relates to the administration of these listings by Services Australia. For further information on broader PBS changes, please visit the PBS website. Relevant information and authority application forms have been updated and can be accessed through the Services Australia website.

Moderate to severe hidradenitis suppurativa

Bimekizumab (160 mg/mL injection, 2 x 1 mL pen devices; 320 mg/2 mL injection, 2 mL pen devices) (Bimzelx®) is now listed on the PBS for the treatment of moderate to severe hidradenitis suppurativa. Authority applications for initial, grandfather and continuing treatments can be made using the Online PBS Authorities system or in writing.

Paroxysmal nocturnal haemoglobinuria (PNH)

Pegcetaoplan (1.08 g/20 mL injection, 20 mL vial) (Empaveli®) has had a change to the restriction for the treatment of PNH. Authority applications for initial, grandfather, continuing and returning treatments can be made using the Online PBS Authorities system or in writing.

Parkinson's disease

Apomorphine hydrochloride hemihydrate (100 mg/20 mL injection, 5 x 20 mL cartridges) (MOVAP0 POD®) is now listed on the PBS for the treatment of Parkinson's disease. Prescriptions for treatment are Authority required (STREAMLINED).

Metastatic or unresectable, well-differentiated malignant pancreatic neuroendocrine tumour (pNET) or extra-pancreatic neuroendocrine tumour (epNET)

Cabozantinib (20 mg tablet; 40 mg tablet; 60 mg tablet) (Cabometyx®) is now listed on the PBS for the treatment of pNET or epNET. Prescriptions for initial and continuing treatments are Authority required (STREAMLINED).

Seizures of the Lennox-Gastaut syndrome

Cannabidiol (100 mg/mL oral liquid, 100 mL) (Epidyolex®) has had an amendment to the restriction level. Prescriptions for treatment are now Authority required (STREAMLINED).

Multiple sclerosis

Ocrelizumab (920 mg/23 mL injection, 23 mL vial) (Ocrevus® SC) is now listed on the PBS for the treatment of multiple sclerosis. Prescriptions for initial and continuing treatments are Authority required (STREAMLINED).

Recurrent or metastatic nasopharyngeal carcinoma

Toripalimab (240 mg/6 mL injection, 6 mL vial) (Zytorvi®) is now listed on the PBS for treatment of recurrent or metastatic nasopharyngeal carcinoma. Prescriptions for treatment are Authority required (STREAMLINED).

1 December 2025 delisted PBS listings

Non-radiographic axial spondyloarthritis; severe psoriatic arthritis; ankylosing spondylitis

Bimekizumab (160 mg/mL injection, 2 x 1 mL pen devices) (Bimzelx®) no longer has a listing for Grandfather arrangements.

Moderate to severe ulcerative colitis

Etrasimod (2 mg tablet) (Velsipity®) no longer has a listing for Grandfather arrangements.

Moderate to severe chronic pouchitis

Vedolizumab (300 mg injection, 1 vial) (Entyvio®) no longer has a listing for Grandfather arrangements.

Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)

Ibrutinib (140 mg capsule; 280 mg tablet; 420 mg tablet) (Imbruvica®) no longer has a listing for Grandfather arrangements.

Venetoclax (venetoclax 10 mg tablet [14] (&) venetoclax 50 mg tablet [7] (&) venetoclax 100 mg tablet [7] (&) venetoclax 100 mg tablet [14], 1 pack; 100 mg tablet) (Venclexta®) no longer has a listing for Grandfather arrangements.

Severe established osteoporosis

Romosozumab (105 mg/1.17 mL injection, 2 x 1.17 mL syringes) (Evenity®) no longer has a listing for Grandfather arrangements.

Von Hippel-Lindau (VHL) disease

Belzutifan (40 mg tablet) (Welireg®) no longer has a listing for Grandfather arrangements.

Severe dry eye syndrome

Soy lecithin + tocopherol + vitamin A (soy lecithin 1% + tocopherol 0.002% + vitamin A palmitate 0.025% spray, 100 actuations) (tearsagain®) has been delisted.

Hormone-dependent metastatic breast cancer in postmenopausal patients

Toremifene (60 mg tablet) (Fareston®) has been delisted.

Prevention and treatment of Infection

Silver sulfadiazine (1% cream, 50 g) (Flamazine®) has been delisted.

Treatment of infection

Flucloxacillin (1 g injection, 5 vials) (Flucil®) has been delisted.

Treatment of allergic reactions; treatment and prevention of vomiting; pre-op, post-op and obstetric sedation

Promethazine (promethazine hydrochloride 50 mg/2 mL injection, 5 x 2 mL ampoules) (DBL Promethazine Hydrochloride®) has been delisted.

Acute post-op and postpartum non-obstructive urinary retention and neurogenic atony of the urinary bladder with retention

Bethanechol (bethanechol chloride 10 mg tablet, 100) (Uro-Carb®) has been delisted.

PBS Authorities – Changes from 1 December 2025

We understand having access to PBS-subsidised medicines can be critical to patient care. That's why Services Australia and the Department of Health, Disability and Ageing are continuing to work together to increase the number of PBS medicines that can be requested and approved using the Online PBS Authorities system (the system).

From 1 December 2025, you will be able to use the system to apply for authority approval and provide evidence digitally for the following medicines. These changes will make it easier for you to request authority approval for these medicines from Services Australia. You will no longer need to submit the written authority application form, details of the proposed prescriptions and test results for certain medicines and treatment phases.

Treatment of severe Crohn's disease (for patients 18 years and older) and fistulising Crohn's disease

Authority applications for initial, change/recommencement and continuing treatments can now be made using the Online PBS Authorities system or in writing. Authority applications for extended induction period (upadacitinib & vedolizumab IV only) can be made using the Online PBS Authorities system or by telephone. Prescriptions for subsequent continuing treatment (biosimilar brands of adalimumab, infliximab IV and ustekinumab only) and continuing treatment or switching treatment from IV to SC (infliximab SC only) are Authority required (STREAMLINED).

Important Information

Uncontrolled severe asthma - dupilumab

Following a review of Services Australia's administration of the Pharmaceutical Benefits Scheme (PBS), prescribers cannot swap patients between dupilumab 200 mg and 300 mg strengths for the treatment of uncontrolled severe asthma. This is because the respective strengths are PBS approved for different patient cohorts. When demonstrating patient eligibility for dupilumab, prescribers will be required to confirm that their patient is not changing strengths. Eligibility Q&As and application forms have been updated.

Submitting Pharmaceutical Benefits Scheme (PBS) Written Applications through Health Professional Online Services (HPOS) form upload

When submitting PBS authority forms through HPOS form upload, it is important to select the correct Form Category. For PBS patients, select PBS Authorities. For DVA patients, select RPBS Authorities. Remember that only yourself or your delegate/s are authorised to upload PBS and RPBS Authority applications.

Make sure you've:

- linked your prescriber number to your Provider Digital Access (PRODA) account for HPOS; and
- Set up your delegations in HPOS.

Visit servicesaustralia.gov.au/HPOS for more information on how to Link your Health Identifiers to HPOS and Manage delegations.

PBS Authorities items criteria

Under the PBS, medicines are made available based on recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC). Patients must meet the set criteria to be eligible for PBS subsidised medicines. Services Australia are unable to provide approval for an Authority Required medication where a patient does not meet the criteria established by PBAC.

If you have concerns or questions about the eligibility criteria set by PBAC, you can contact the Department of Health, Disability and Ageing by email at pbs@health.gov.au.

Reminders

PBS Authorities – written authority application forms

To align with PBS listing changes, forms are updated on the first of the month. Using the most recent form will help avoid delays in obtaining authority approval. Search the Services Australia website to access the most recent forms.

Correct PBS item code

When prescribing PBS medicines via the Online PBS Authorities system, ensure you have selected the correct medicine to match what is on the prescription. This will avoid delays with providing patients with the medication they require.

Ensuring you are providing accurate data

It's important to ensure you are providing accurate and up to date information when completing an authority application. Failure to do so may result in your authority request being rejected.

More information

For more information about the Online PBS Authorities system visit www.servicesaustralia.gov.au/hppbsauthorities

Services Australia has a broad range of educational resources on the Health Professional Education Resources website. This includes simulations, podcast and an infographic on the Online PBS Authorities system. Visit <https://hpe.servicesaustralia.gov.au/pharmaceutical-benefits-scheme.html>

Visit servicesaustralia.gov.au/hpwrittenauthoritydrugs on the Services Australia website to find the most up to date authority application form for each drug, program or condition.